Kiora Pharmaceuticals posts net income in Q3 amid ongoing clinical trials
Tweet Send to a Friend
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported net income of $27,000 for the third quarter of 2025, compared to a net ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
